Epidemiological aspects of the formation of new risks of morbidity and treatment of tuberculosis among the population.

E. V. Bulycheva, E.V. Bulychev
{"title":"Epidemiological aspects of the formation of new risks of morbidity and treatment of tuberculosis among the population.","authors":"E. V. Bulycheva, E.V. Bulychev","doi":"10.21045/1811-0185-2024-2-114-123","DOIUrl":null,"url":null,"abstract":"In accordance with the instruction of the Minister of Health of the Russian Federation No. 19 dated 02/07/2023, specialists currently face several important tasks: from 2015 to 2025, to reduce the incidence of tuberculosis, as well as the number of deaths from tuberculosis by 75%. To do this, it is necessary to identify all the risk factors that may create difficulties in achieving these goals. Purpose of the study is to characterize the epidemiological aspects of the formation of new risks of morbidity and treatment of tuberculosis among the population. Materials and methods. An analysis was carried out among newly identified patients with tuberculosis by molecular genetic (n=1682) and bacterial (n=1630) research methods in the period from 2017 to 2020 according to drug resistance indicators. Results. It was found that in the period from 2015 to 2017, the indicators of drug resistance in tuberculosis patients were almost at the same level. The leading antimicrobial drugs in demand among the population were ceftriaxone, azithromycin, levofloxacin, moxifloxacin. The maximum increase in sales in 2020 relative to 2019 data to 150% was determined among quinolone derivatives of moxifloxacin and levofloxacin, which began to be used in the treatment of coronavirus infection. At the same time, these drugs are traditionally used to treat tuberculosis, but in 2020, an alarming trend was revealed, which was that drug resistance was detected in patients with tuberculosis to these drugs. Among newly diagnosed tuberculosis patients, from 2018 to 2020, an increase in the proportion of patients with primary drug resistance to levofloxacin and moxifloxacin was established by 189-480%; whereas for other antibiotics, the increase averaged up to 60.8%. Findings. The findings suggest an alarming scenario in which drug resistance develops towards highly virulent and highly resistant to antibacterial drugs genotypes.","PeriodicalId":496589,"journal":{"name":"Manager Zdravookhranenia","volume":"39 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Manager Zdravookhranenia","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.21045/1811-0185-2024-2-114-123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In accordance with the instruction of the Minister of Health of the Russian Federation No. 19 dated 02/07/2023, specialists currently face several important tasks: from 2015 to 2025, to reduce the incidence of tuberculosis, as well as the number of deaths from tuberculosis by 75%. To do this, it is necessary to identify all the risk factors that may create difficulties in achieving these goals. Purpose of the study is to characterize the epidemiological aspects of the formation of new risks of morbidity and treatment of tuberculosis among the population. Materials and methods. An analysis was carried out among newly identified patients with tuberculosis by molecular genetic (n=1682) and bacterial (n=1630) research methods in the period from 2017 to 2020 according to drug resistance indicators. Results. It was found that in the period from 2015 to 2017, the indicators of drug resistance in tuberculosis patients were almost at the same level. The leading antimicrobial drugs in demand among the population were ceftriaxone, azithromycin, levofloxacin, moxifloxacin. The maximum increase in sales in 2020 relative to 2019 data to 150% was determined among quinolone derivatives of moxifloxacin and levofloxacin, which began to be used in the treatment of coronavirus infection. At the same time, these drugs are traditionally used to treat tuberculosis, but in 2020, an alarming trend was revealed, which was that drug resistance was detected in patients with tuberculosis to these drugs. Among newly diagnosed tuberculosis patients, from 2018 to 2020, an increase in the proportion of patients with primary drug resistance to levofloxacin and moxifloxacin was established by 189-480%; whereas for other antibiotics, the increase averaged up to 60.8%. Findings. The findings suggest an alarming scenario in which drug resistance develops towards highly virulent and highly resistant to antibacterial drugs genotypes.
在人群中形成新的结核病发病和治疗风险的流行病学方面。
根据俄罗斯联邦卫生部 2023 年 7 月 2 日第 19 号指令,专家们目前面临着几项重要任务:从 2015 年到 2025 年,将结核病发病率以及因结核病死亡的人数减少 75%。为此,有必要找出可能给实现这些目标带来困难的所有风险因素。本研究的目的是从流行病学的角度分析在人群中形成结核病发病和治疗新风险的特点。材料和方法。根据耐药性指标,通过分子遗传学(n=1682)和细菌学(n=1630)研究方法,对 2017 年至 2020 年期间新发现的肺结核患者进行分析。结果显示研究发现,2015 年至 2017 年期间,肺结核患者的耐药性指标基本处于同一水平。人群需求量居前的抗菌药物为头孢曲松、阿奇霉素、左氧氟沙星、莫西沙星。莫西沙星和左氧氟沙星的喹诺酮类衍生物在 2020 年的销售额相对于 2019 年的数据增幅最大,达到 150%,这些药物开始用于治疗冠状病毒感染。同时,这些药物传统上用于治疗肺结核,但在 2020 年,一个令人担忧的趋势显现出来,那就是在肺结核患者中发现了对这些药物的耐药性。在新确诊的肺结核患者中,从 2018 年到 2020 年,对左氧氟沙星和莫西沙星产生初级耐药性的患者比例增加了 189%-480%;而对其他抗生素,平均增幅高达 60.8%。研究结果。研究结果表明,抗药性向高毒性和高抗药性基因型发展的情况令人担忧。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信